Daxor logo

DXR - Daxor News Story

$10.74 -0.3  -3.0%

Last Trade - 9:10pm

Micro Cap
Market Cap £33.0m
Enterprise Value £34.1m
Revenue £200k
Position in Universe 6092nd / 7405

New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care

Tue 9th November, 2021 1:00pm
For best results when printing this announcement, please click on link below:

Data Presented at the NeuroCritical Care Society 19(th) Annual Meeting 2021

Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With
Non-Traumatic Subarachnoid Hemorrhage (nSAH)

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR),
the global leader in blood volume measurement technology, today announces new
data demonstrating the clinical utility of the BVA-100 blood test in patients
with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual
NeuroCritical Care Society (NCS) 19(th) Annual Meeting.

The study titled, “The Influence of Blood Volume Analysis on the Clinical
Management of Non-Traumatic Subarachnoid Hemorrhage,” surveyed whether
intravascular volume assessments would influence clinical decision making in
nSAH. The data showed 69% responded with different management strategies after
being provided with BVA results. Lindsey Carvalho M.D., lead investigator
concluded, “All participants indicated a preference for BVA over invasive
hemodynamic monitoring if given an option of either modality to monitor volume
status in nSAH due to the former’s less invasive nature.”

Prior research presented at NCS in 2020 titled the “Blood Volume Analysis in
the Management of Volume Status in Non-Traumatic Subarachnoid Hemorrhage,”
studied whether BVA would change clinical practice guidelines for management
of nSAH to prevent Delayed Cerebral Ischemia (DCI) during the high-risk
periods. Of the BVA tests completed, 54% resulted in a change of treatment
management after interpretation of the BVA test results.

“Non-traumatic subarachnoid hemorrhage can cause complicated, irreversible
neurological injury and achieving optimal intravascular volume plays an
important role in improving patient outcomes,” said Michael Feldschuh, CEO
and President of Daxor Corporation. “These new data further demonstrate that
Daxor’s unique blood volume measurement helps guide physicians to
effectively determine treatment options to manage fluid derangements for these
critically-ill patients and is the driver of this test for standard clinical

Prior data in the area of Surgical ICU Management showed a similarly high
level of BVA-100 tests resulting in a change of treatment strategy. In a
randomized control trial (RCT) published in the journal Shock, the BVA-100
test has shown to reduce ICU mortality by 66% (P=0.03) and reduce ventilator
days in patients suffering predominantly from acute respiratory distress
syndrome and septic shock. Additionally, the analysis showed 44% of BVA test
results led to a change in treatment strategy (P=0.004) that care teams would
not have performed absent the data from the BVA volume status measure.

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement
technology focused on blood volume testing innovation (organized as an
investment company with fully-owned innovative medical instrumentation and
biotechnology operations). We developed and market the BVA-100(®) (Blood
Volume Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume status and
composition compared to patient-specific norms. The BVA technology enhances
hospital performance metrics in a broad range of surgical and medical
conditions, including heart failure and critical care, by informing treatment
strategies, resulting in significantly improved multiple measures of patient
outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal blood
volume for all. For more information, please visit our website at Daxor.com

Forward-Looking Statements

Certain statements in this release may include forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995,
including without limitation, statements regarding the impact of hiring sales
staff and expansion of our distribution channels. Forward-looking statements
are predictions, projections and other statements about future events that are
based on current expectations and assumptions and, as a result, are subject to
risks and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this release,
including, without limitation, those risk associated with our post-market
clinical data collection activities, benefits of our products to patients, our
expectations with respect to product development and commercialization
efforts, our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual property
protection, FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with and benefits
from acquired businesses, and additional other risks and uncertainties
described in our filings with the SEC. Forward-looking statements speak only
as of the date when made. Daxor does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR


GlobeNewswire, Inc. 2021
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.